I think there is bound to be a worldwide market for SNG but we have no patent protection at present for anywhere other than US and Europe/UK as far as I understand. I don't know the company plans for rolling this out worldwide or the rules re patents but I would expect SNG would want to partner with large Pharma in India or China and make urgent patent application in order to protect IP in RoW.
Spinnaker
Turkishdreams
That is an uplifting story and fantastic that you will achieve your dreams after four horrible years. Congratulations.
Very best wishes for Christmas and a healthy 2021 and beyond to you and your husband.
Spinnaker
Docdaneeka
I just spoke to a doctor friend, just retired this year. She said she didn't know until today that the vaccine wasn't proven to prevent transmission. That is a different point but reinforces yours that the information campaign through all formats is vital.
Spinnaker
It's all very well pontificating but nobody knows why the share price has risen or if there are discussions on sale.
For what it is worth my thoughts are.
1) I really expected a tie in with a large US pharma following P2 results in July leading to swift roll-out of P3 and probable EUA by November and/or full US licence by now.
2) There are only two reasons that I can think of that this didn't happen, either
a) RM and the board wanted too much of the pie and all offers were refused, or
b) None of the large Pharmas made an offer since they thought it was too high risk for the cost.
3) If the above is true, what has changed? There are no further research outcomes or approvals to date, only the Lancet Peer review which hasn't changed the basics.
4) Half of the money raised at 175p is going towards international P3 trials which haven't started yet as far as we know and there is no indication of read-out date. Likely to be at least 3 months and possibly more.
5) SNG are now funded to complete P3 trials and the Board will be anticipating very good results. I therefore think it is unlikely that RM would have reduced his value expectation since July and therefore acceptance of an offer near 175p is unthinkable.
Spinnaker
Legalwolf
Can I ask? Are you thinking that N.D.A. means Non Disclosure Agreement or New Drug Application?
When I first read your post, the former was my immediate assumption which is more in my field of knowledge but I recently read another poster that stated it meant the latter. Your post appears to imply the former.
Many thanks
Feeling imbecilic, Spinnaker
Thanks for your responses. I see two common Directors. I was fairly gobsmacked to see that TILS has had 36 Officers over the past 25 years and all but 5 have resigned!
I should have done a bit more DD here.
Spinnaker
I do think that the BoD here has been pretty damn subterranean in its communication with shareholders since the massive pumping before the fund raising both placing and ATM. Admittedly this was compounded by silly US confusion with TESLA. The confusion on time difference between UK and US split dates was more than unhelpful. However the current shenanigans with the de-merger of Accustem and listing for TILS on the main market is really screwing confidence even more.
I don't have a clue whether there is a Board of Directors for Accustem, whether there are any employees or premises. All I understand is the company will have £1m plus some IP relating to breast cancer products, Therefore is it really just a shell that can't go anywhere without being purchased or requiring significant fundraising? I am sure you are correct John Law. There was a load of hype on this board suggesting the de-merger would result in a massive windfall to TILS holders. I never really accepted that view and there was certainly no rush into the shares before de-merger. I really can't see significant value in Accustem now unless negotiations are already very far advanced for a sale of the new company. The date for trading of new shares has not yet been announced and will not now be until January or later if it actually occurs. I expect talk of £1 per share is totally pie in the sky unless there is a large buyer.
I am well underwater in TILS and wish I had the confidence of Shiraz to invest more funds to reduce my average even on a medium/long term view. I agree with other posters that the BoD have not taken advice of the right calibre judging by what has happened over the last six months. Certainly the short term does not show any likelihood of earnings potential even post the Phase 1 trial in Brazil for Covid treatment.
Now a rather concerned investor but one who will have to continue holding now I see a fairly limited downside at this SP.
Spinnaker
Thanks Floater and Welsh Falcon. I understand and and think your points are well made. A symbiotic relationship between Newcrest and Greatland is good for both parties and lets hope the excellent relationship continues. It looks like the GB / EU relationship is coming under pressure under pressure unfortunately.
Spinnaker
Welsh Falcon
I was concerned whether Mining News were pricing in US or AUS $ but it seems to be AUS $.
At an average of A$2500 per oz AISC it would seem that Telfer is breaking even, not running at a huge loss since A $2,500 was the average spot price for gold during the period reported. At current rates it seems US$1800 p oz = AUS$2,400 so not huge losses keeping Telfer open.
Nevertheless this does not detract from Paddy's point that the average cost of extraction at Telfer seems to be increasing fast and therefore without Havieron or a significant PoG increase Telfer would probably have to close soon.
Surely this bodes well for GGP's negotiating strength and also the speed that Newcrest will want to progress to mining as others have stated. All very positive combined with possible inclusion in GDX next March
Spinnaker
Now I have confused myself.
What I suppose happens is if GGP SP moves in line with other miners then the number of shares required to be held by GDXJ will remain the same but since GGP has undoubtedly been outperforming the market the proportion of capital value of GGP required to be held would increase and I suppose you have a point. This would be automatically be reflected in the increased value of the GGP holding due to the SP increase. Therefore is there any significant share sale or purchase required?
Spinnaker
SG
I believe the GDXJ proportion will increase with increase in MC not the opposite.
I am delighted that GGP is the one share I have that is doing its best to offsett huge losses in some other holdings. Thanks very much for the excellent postings here from Paddy, Hydrogen etc. This has been the share that has caused me least concern since what has been found cannot be lost.
Spinnaker
LiveLif
I entirely agree with your quote. The only problem is your initial statement is 'non sequitor'. Asymptomatic individuals are not generally tested nor contacts traced. You will note the word 'illness' is used implying symptoms.
Spinnaker
Yes Borsac
Thanks for that link. This is what Michael Mina and others have been saying for months. The fact is that our testing in the UK is usually done on symptomatic individuals possibly 24 to 48 hours after first symptoms. Symptoms first occur between two and five days after infection Results probably 24 to 48 hours after tests. This means that test results are only available between 4 days minimum and 9 days maximum after infection and, according to Mina, well after peak infectiousness which is almost always before symptoms occur and probably within 48 hours of initial infection. Obviously asymptomatic individuals which may be the majority are entirely missed by the tests because they won't have one unless part of a trial/mass community testing process.
The upshot of this is that our current testing regime will only have a very minor impact on preventing the spread of the disease whilst insisting people quarantine when for the most part they will be no longer infectious .
Spinnaker
Thanks for that Chris T and crippz.
I am at total fault here since I only red the first couple of pages of the 14 Oct RNS despite then applying for a ridiculously large number of placing shares. I see that is £30m accounted for then.
Spinnaker
Parexel Biotech have 20,000 employees based in Boston Mass and assist in running clinical trials for their clients and also getting new drugs to market.
It could be they habe been brought in for the USA to assist Synairgen since Clinigen's brief is only EU and UK.
Spinnaker
sarahrodz
Thanks for that interesting link. It seems Parexel Biotech are partnering over 100 companies in the Covid field and from the interview Synairgen was the first and dated from the initial phase of the pandemic. All I can say is that it is not at all clear what is the basis of this partnership and how it has assisted SNG.
I must say I haven't yet checked out the american company or our RNSs for reference.
Spinnaker